GLP-1 drugs are shrinking appetites and supercharging demand for nutrient-dense, snackable formats. Precision eating is rewriting menus and appears to be reshaping the future of food, drink, and wellness.
Recent moves in the yogurt segment from CPG giants signal a strong category foundation heading into an uncertain economic future—a white horse amid other stagnating retail categories. Danone, for example, beat out analyst expectations with its Q1 sales.
The rapid adoption of weight-loss drugs is reshaping purchasing habits. Circana experts highlight opportunities for brands to align with GLP-1 users’ goals by offering tailored, portion-controlled products and leveraging personalized marketing strategies to capture this evolving market.
